Disease · MONDO_0001063

cardia cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cardia cancer. Diseases, record MONDO_0001063. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001063

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cardia cancer; Open Targets
Open Targets ID: MONDO_0001063; Open Targets
Other names: cancer of cardia of stomach, cardia of stomach cancer, malignant cardia of stomach neoplasm, malignant neoplasm of cardia of stomach; Open Targets
Disease Ontology: DOID:10548; Disease Ontology
Highest stage of its drugs: Phase 2, for 5 of its 8 drugs, from ClinicalTrials.gov; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 2	ClinicalTrials.gov	3	3	2	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
CETUXIMAB	CHEMBL1201577	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
TRASTUZUMAB	CHEMBL1201585	Antibody	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TYMS	Thymidylate synthase	2	Thymidylate synthase inhibitor	Phase 2	https://conductscience.org/library/genes/7298	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	1	Receptor protein-tyrosine kinase erbB-2 inhibitor	Unknown	https://conductscience.org/library/genes/2064	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Unknown	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Unknown	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin inhibitor	Unknown	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin inhibitor	Unknown	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	1	Tubulin inhibitor	Unknown	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	1	Tubulin inhibitor	Unknown	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	1	Tubulin inhibitor	Unknown	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01362127	Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia	Phase 2	181	2020-02-26	Carcinoma, Squamous Cell, Adenocarcinoma of the Esophagus and Gastric Cardia	CISPLATIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02636088	Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer	Phase 2	51		Esophageal Neoplasm	CETUXIMAB, FLUOROURACIL, OXALIPLATIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01295086	Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer	Not applicable	27		Adenocarcinoma	CAPECITABINE, DOCETAXEL, OXALIPLATIN, TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Radiochemotherapy vs Chemotherapy: Safety of Respective Neoadjuvant Therapies.	79 of 90	81 of 91	181	NCT01362127	Trial comparisons
Radiochemotherapy vs Chemotherapy: serious adverse events	57 of 90	41 of 91	181	NCT01362127	Trial comparisons
Radiochemotherapy vs Chemotherapy: Pathological Complete Histological Response (pCR) After Resection Than Chemotherapy Alone in Patients With Resectable Carcinoma of the Esophagus and Cardia.	22 of 78	7 of 78	156	NCT01362127	Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31436322	RESULT	1	PubMed
30137281	RESULT	1	PubMed
30084992	RESULT	1	PubMed
26782957	RESULT	1	PubMed
25908010	RESULT	1	PubMed
27254026	DERIVED	1	PubMed
25582305	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001063

GET https://conductscience.org/api/diseases/v1/MONDO_0001063/drugs

API reference For AI assistants